![Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review | Diabetes Therapy Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review | Diabetes Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs13300-023-01386-5/MediaObjects/13300_2023_1386_Fig5_HTML.png)
Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review | Diabetes Therapy
![Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions | American Board of Family Medicine Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions | American Board of Family Medicine](https://www.jabfm.org/content/jabfp/32/3/431/F1.large.jpg)
Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions | American Board of Family Medicine
![2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Diabetologia 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Diabetologia](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00125-019-05039-w/MediaObjects/125_2019_5039_Fig2_HTML.png)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Diabetologia
![Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/asset/82f46f7d-402a-48bc-93ba-bcf719139a9f/gr1.jpg)
Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology
![JCM | Free Full-Text | Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes JCM | Free Full-Text | Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes](https://www.mdpi.com/jcm/jcm-09-00912/article_deploy/html/images/jcm-09-00912-g001.png)
JCM | Free Full-Text | Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
![Edgar V. Lerma 🇵🇭 on X: "Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/E11n7xQkjL https://t.co/ZqqvqpZeWt" / X Edgar V. Lerma 🇵🇭 on X: "Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/E11n7xQkjL https://t.co/ZqqvqpZeWt" / X](https://pbs.twimg.com/media/DrrCSHUXgAIxaCB.jpg:large)
Edgar V. Lerma 🇵🇭 on X: "Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/E11n7xQkjL https://t.co/ZqqvqpZeWt" / X
![Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline | Primary Care IPA Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline | Primary Care IPA](https://primarycareipa.org/wp-content/uploads/2020/11/pt-chart1.38_1.jpg)